• 1
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 829.
  • 2
    Travis W, Travis, LB, Devesa, SS. Lung cancer incidence and survival by histologic type. Cancer. 1995; 75(1 Suppl ): 191202.
  • 3
    Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999; 86: 18671876.
  • 4
    Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with Stage III non-small cell lung cancer. Semin Radiat Oncol. 2000; 10: 289295.
  • 5
    Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002; 20: 23s33s.
  • 6
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899909.
  • 7
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 8
    Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001; 34( Suppl 3): S75S80.
  • 9
    Rosell R, Taron M, Alberola V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer. 2003; 41( Suppl 1): S97S102.
  • 10
    Pickett CB, Lu AYH. Glutathione S-transferases: gene structure, regulation, and biological function. Annu Rev Biochem. 1989; 58: 743764.
  • 11
    Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995; 30: 445600.
  • 12
    Seidegard J, Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect. 1997; 105( Suppl 4): 791799.
  • 13
    Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH. An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. Am J Pathol. 1990; 137: 845853.
  • 14
    Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 1989; 49: 14221428.
  • 15
    Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997; 272: 1000410012.
  • 16
    Reinemer P, Dirr HW, Ladenstein R, et al. Three-dimensional structure of class pi glutathione S-transferase from human placenta in complex with S-hexylglutathione at 2.8 A resolution. J Mol Biol. 1992; 227: 214226.
  • 17
    Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1–1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994; 224: 893899.
  • 18
    Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998; 19: 275280.
  • 19
    Ryberg D, Skaug V, Hewer A, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997; 18: 12851289.
  • 20
    Jourenkova-Mironova N, Wikman H, Bouchardy C, et al. Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenetics. 1998; 8: 495502.
  • 21
    To-Figueras J, Gene M, Gomez-Catalan J, et al. Genetic polymorphism of glutathione S-transferase P1 gene and lung cancer risk. Cancer Causes Control. 1999; 10: 6570.
  • 22
    Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics. 1998; 8: 2731.
  • 23
    Wang Y, Spitz MR, Schabath MB, Ali-Osman F, Mata H, Wu X. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer. 2003; 40: 2532.
  • 24
    Nakagawa K, Saijo N, Tsuchida S, et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem. 1990; 265: 42964301.
  • 25
    Ban N, Takahashi Y, Takayama T, et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 1996; 56: 35773582.
  • 26
    Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radical Res. 1999; 31: 549558.
  • 27
    Matsunaga T, Sakamaki S, Kuga T, et al. GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice. Hum Gene Ther. 2000; 11: 16711681.
  • 28
    Hida T, Kuwabara M, Ariyoshi Y, et al. Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer. Potential predictive value in chemotherapeutic response. Cancer. 1994; 73: 13771382.
  • 29
    Bai F, Nakanishi Y, Kawasaki M, et al. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer. 1996; 78: 416421.
  • 30
    Inoue T, Ishida T, Sugio K, Maehara Y, Sugimachi K. Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration. 1995; 62: 223227.
  • 31
    Nakanishi Y, Kawasaki M, Bai F, et al. Expression of p53 and glutathione S-transferase-Pi relates to clinical drug resistance in non-small cell lung cancer. Oncology. 1999; 57: 318323.
  • 32
    FlemingID, CooperJS, HensonDE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1998.
  • 33
    Spitz MR, Shi H, Yang F, et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst. 1998; 90: 358363.
  • 34
    Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2003; 12: 527533.
  • 35
    Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 1996; 56: 37253730.
  • 36
    Yang P, Yokomizo A, Tazelaar HD, et al. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer. 2002; 35: 221229.
  • 37
    Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2002; 94: 936942.
  • 38
    Olak J, Colson Y. Gender differences in lung cancer: have we really come a long way, baby? J Thorac Cardiovasc Surg. 2004; 128: 346351.